文献速递头颈部肿瘤放疗

头颈部重建皮瓣术后放疗:多中心XFLAP1研究

Head and neck radiotherapy after reconstructive flap surgery: Results of the multicentric XFLAP1 study.
PubMed 文献 · Radiother Oncol · 2026-02-10

XFLAP1多中心回顾性队列纳入2018—2023年355例头颈部肿瘤皮瓣重建术后接受术后放疗(PORT)±同步化疗的患者,量化复发相对皮瓣的分布。全皮瓣体纳入CTV者占66%,皮瓣体内复发仅3例(1%),2年LRR累积发生率15.8%、转移16.7%、OS 74.6%。结论支持以交界区为重点的CTV并弱化皮瓣体,待前瞻性验证。

要点

  • 多数局部失败位于自体组织-皮瓣交界或非皮瓣部位,皮瓣体内复发罕见。
  • 66%计划将整个皮瓣体纳入CTV,皮瓣体中位剂量65.3 Gy、蒂Dmax 67.5 Gy。
  • 上述数据支持交界区聚焦CTV、弱化皮瓣体以减少并发症,尚需前瞻性验证。

核心结论

  • 皮瓣体中心区域复发罕见,多数局部失败累及自体组织-皮瓣交界或非皮瓣部位。
  • 数据支持采用以交界区为重点的CTV并弱化皮瓣体以限制并发症,但需前瞻性验证。

研究设计与样本

  • 多中心回顾性XFLAP1队列(2018—2023),头颈部肿瘤患者行肿瘤切除联合皮瓣重建后接受PORT±同步化疗。
  • 共355例、来自8个中心;游离皮瓣239例(67%),区域带蒂皮瓣69例(33%)。
  • 在可获得的计划CT上事后勾画皮瓣(勾画皮瓣N=153);采用竞争风险(Fine-Gray)估计LRR与转移,Kaplan-Meier估计OS。

主要发现

  • 中位随访32.9个月,120/355(34%)例复发,其中LRR 68例(19%)、转移71例(20%)。
  • LRR中位时间7.35个月;仅3例(1%)复发发生于皮瓣体内。
  • 2年累积发生率:LRR 15.8%,转移16.7%;2年OS 74.6%。
  • 多因素分析中pN2-3预测转移;LRR、转移及ECOG≥1与更差OS相关。

关键数值与推荐

  • 66%的计划将整个皮瓣体纳入CTV。
  • 勾画皮瓣中,皮瓣体中位剂量65.3 Gy,蒂Dmax 67.5 Gy(N=153)。

临床怎么用

  • 术后CTV勾画可将重点放在自体组织-皮瓣交界区,弱化皮瓣体照射以限制并发症。
  • 关注pN2-3患者的转移风险,以及LRR、转移和ECOG≥1对生存的不良影响。

局限性

  • 为回顾性多中心队列,皮瓣勾画为事后在可获得的计划CT上完成(N=153)。
  • 交界区聚焦CTV的策略尚待前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Postoperative target delineation after reconstructive surgery in head and neck cancer (HNC) is heterogeneous; whether to include the flap or focus on the native tissue-flap junction is debated. We quantified patterns of relapse relative to flaps and summarized practice, toxicity and function. MATERIALS AND METHODS: in the retrospective XFLAP1 cohort (2018-2023), patients with HNC underwent tumor resection with flap reconstruction and postoperative radiotherapy (PORT) ± concurrent chemotherapy. Competing-risks (Fine-Gray) estimated locoregional relapse (LRR) and metastases; overall survival (OS) used Kaplan-Meier. Flaps were contoured a posteriori on planning CTs, when available. RESULTS: Of 355 patients across eight centres, free flaps were used in 239 (67%) and regional pedicled flaps in 69 (33%). The entire flap body was encompassed in the CTVs in 66% of plans; median flap-body dose was 65.3 Gy and pedicle Dmax 67.5 Gy for the delineated flaps (N = 153). Median follow-up was 32.9 months, 120/355 (34%) patients relapsed, including 68 (19%) LRR and 71 (20%) metastases. Median time to LRR was 7.35 months; only 3 (1%) of relapses arose within the flap body. Two-year cumulative incidence was 15.8% for LRR and 16.7% for metastases; two-year OS was 74.6%. On multivariable analysis, pN2-3 predicted metastases; LRR, metastases, and ECOG ≥ 1 were associated with worse OS. CONCLUSIONS: relapses in the flap-body epicentre were rare; most local failures involved the native tissue-flap junction or non-flap sites. These data support junction-focused CTVs with reduced emphasis of the flap body to limit morbidity, pending prospective validation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Di Rito A, Blache A, Preudhomme R, et al. Head and neck radiotherapy after reconstructive flap surgery: Results of the multicentric XFLAP1 study. Radiother Oncol. 2026. PMID: 41679554. doi:10.1016/j.radonc.2026.111437

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。